Jewish General Hospital
Montreal, Quebec, Canada
Location status: Recruiting
Location contact
Jillian Kifell, MSc
CONTACT
5143408222 ext. 25806
Michael J Goldfarb, MD, MSc
PRINCIPAL_INVESTIGATOR
NCT Number: NCT06588101
There is a need to identify strategies that improve the conduct of clinical trials involving family members of intensive care unit (ICU) patients. The purpose of the present study is to evaluate recruitment and retention strategies for clinical trials involving family members of ICU patients. 4 strategies (2 recruitment and 2 retention) will be tested. Investigators will integrate the strategies into three existing studies that involve family members of ICU patients. Participants will be randomized using a 2x2 factorial design. The co-primary outcomes are recruitment percentage (participants enrolled/participants approached) and retention percentage (participants completing follow-up/participants enrolled).
Interested in participating?
Request Info18 year and older
All sexes
Interventional
Not applicable
Montreal, Quebec, Canada
Location status: Recruiting
Jillian Kifell, MSc
CONTACT
5143408222 ext. 25806
Michael J Goldfarb, MD, MSc
PRINCIPAL_INVESTIGATOR
Family engagement in the ICU is recommended by critical care professional societies, but insufficient evidence of its benefits for patients and family members has hindered clinical uptake. Thus, high-quality evidence is needed to promote and support family engagement practices. A specific unmet need is to identify strategies to improve the recruitment and retention of families in clinical trials in the ICU setting. The objective of this study is to evaluate recruitment and retention strategies for clinical trials involving family members in the ICU setting.
Methodological Approach: Investigators will use a Study Within a Trial (SWAT) design to embed a factorial randomized trial of 160 participants enrolled across investigator group's three ongoing studies involving family members of ICU patients: FAME, VR-Family, and NGAGE. Investigators expect 160 participants to be enrolled over a 6-month period. Participants will be randomized by 2x2 factorial design to selected recruitment and/or retention strategies. The co-primary outcomes will be (1) recruitment rate and (2) retention rate.
Healthy volunteers accepted: No
Only the study team can determine whether someone qualifies for participation.
Inclusion criteria
Exclusion criteria
Potential participants are provided a visual infographic depicting the key elements of the written consent form in addition to the standard written consent form.
Potential participants are provided an e-gift card to Amazon or Second Cup as a reward for completing the enrollment questionnaire.
Time frame: At enrolment
Family member participants enrolled/ family member participants approached
Time frame: From enrolment until 6 month follow-up completion
Family member participant completing follow-up/family member participants enrolled
Contact information is provided by the study sponsor or research team.
Lady Davis Institute
Other
Clinical Trial Recruitment and Retention Strategies for Family Members in the Intensive Care Unit: A Study Within A Trial Randomized Design
Acronym: SWAT
OpenTrials presents study information sourced from ClinicalTrials.gov. The official registry record should be consulted for the latest information.
View the official ClinicalTrials.gov record (opens in a new tab)This listing is for discovery and informational purposes only. It is not medical advice, does not guarantee that a study is recruiting, and does not determine eligibility. Contact the study team and a qualified healthcare professional when considering participation.
Published trials that share one or more normalized conditions with this study.
NCT05776641
Alzheimer Disease, Brain Diseases
Boston, Massachusetts, United States
View Trial DetailsNCT06090240
Advance Care Planning, Advance Directives
Hong Kong
View Trial DetailsNCT05929703
Aging, Alzheimer Disease
Orange, California, United States
View Trial DetailsNCT06945055
Family Members, Implementation
Bend, Oregon, United States
View Trial Details